VKH
GNMX

Virtu KCG Holdings’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Virtu KCG Holdings’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$35K Buy
+26,671
New +$38.5K ﹤0.01% 2661

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Virtu KCG Holdings's GNMX Position: Q2 2017 in Review

Virtu KCG Holdings opened a new position in Aevi Genomic Medicine Inc (GNMX) in Q2 2017: 26,671 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #2661 among its holdings.

51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Virtu KCG Holdings held 26,671 shares of Aevi Genomic Medicine Inc worth $35K as of Q2 2017.
  • Aevi Genomic Medicine Inc was a new Virtu KCG Holdings position in Q2 2017.
  • Aevi Genomic Medicine Inc made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2661 holding.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.